
Francois Dabis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3168678/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet, The, 2002, 360, 119-129.	6.3	1,415
2	Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet, The, 2006, 367, 817-824.	6.3	1,030
3	Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet, The, 2004, 364, 1236-1243.	6.3	1,026
4	Liver-Related Deaths in Persons Infected With the Human Immunodeficiency Virus. Archives of Internal Medicine, 2006, 166, 1632.	4.3	1,004
5	Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet, The, 2008, 371, 1417-1426.	6.3	809
6	Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet, The, 2009, 373, 1352-1363.	6.3	676
7	Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Antiâ€HIV Drugs (D:A:D) Study. Journal of Infectious Diseases, 2010, 201, 318-330.	1.9	575
8	6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. Lancet, The, 1999, 353, 786-792.	6.3	491
9	Late Postnatal Transmission of HIVâ€1 in Breastâ€Fed Children: An Individual Patient Data Metaâ€Analysis. Journal of Infectious Diseases, 2004, 189, 2154-2166.	1.9	442
10	Postnatal Transmission of Human Immunodeficiency Virus Type 1 from Mother to Infant. New England Journal of Medicine, 1991, 325, 593-598.	13.9	370
11	HIV-Infected Adults With a CD4 Cell Count Greater Than 500 Cells/mm3 on Long-Term Combination Antiretroviral Therapy Reach Same Mortality Rates as the General Population. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 72-77.	0.9	348
12	Eearly loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bulletin of the World Health Organization, 2008, 86, 559-567.	1.5	275
13	Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Medicine, 2013, 10, e1001510.	3.9	256
14	International multicentre pooled analysis of late postnatal mother-to-child transmission of HIV-1 infection. Lancet, The, 1998, 352, 597-600.	6.3	238
15	Cohort Profile: The international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa. International Journal of Epidemiology, 2012, 41, 1256-1264.	0.9	224
16	Transfer and Evaluation of an Automated, Low-Cost Real-Time Reverse Transcription-PCR Test for Diagnosis and Monitoring of Human Immunodeficiency Virus Type 1 Infection in a West African Resource-Limited Setting. Journal of Clinical Microbiology, 2005, 43, 2709-2717.	1.8	221
17	HIV-1/AIDS and maternal and child health in Africa. Lancet, The, 2002, 359, 2097-2104.	6.3	217
18	All-cause mortality in treated HIV-infected adults with CD4 >=500/mm3 compared with the general population: evidence from a large European observational cohort collaborationA. International Journal of Epidemiology, 2012, 41, 433-445.	0.9	217

#	Article	IF	CITATIONS
19	HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet, The, 2006, 368, 451-458.	6.3	209
20	Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America. Aids, 2015, 29, 221-229.	1.0	208
21	Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysisâ€. International Journal of Epidemiology, 2007, 36, 1009-1021.	0.9	207
22	Natural History of Human Immunodefiency Virus Type 1 Infection in Children: A Five-Year Prospective Study in Rwanda. Pediatrics, 1999, 104, e56-e56.	1.0	205
23	Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet, The, 2010, 376, 449-457.	6.3	203
24	Incidence of Tuberculosis among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy in Europe and North America. Clinical Infectious Diseases, 2005, 41, 1772-1782.	2.9	197
25	Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. Aids, 2008, 22, 395-402.	1.0	188
26	Response to combination antiretroviral therapy: variation by age. Aids, 2008, 22, 1463-1473.	1.0	188
27	Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial. Lancet HIV,the, 2018, 5, e116-e125.	2.1	187
28	Gender and the Use of Antiretroviral Treatment in Resource-Constrained Settings: Findings from a Multicenter Collaboration. Journal of Women's Health, 2008, 17, 47-55.	1.5	178
29	Rapid scaling-up of antiretroviral therapy in 10 000 adults in Côte d'Ivoire: 2-year outcomes and determinants. Aids, 2008, 22, 873-882.	1.0	168
30	Antiretroviral therapy in resourceâ€imited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in subâ€Saharan Africa, Asia and Latin America. Tropical Medicine and International Health, 2008, 13, 870-879.	1.0	162
31	Prevalence and factors associated with depression in people living with HIV in sub-Saharan Africa: A systematic review and meta-analysis. PLoS ONE, 2017, 12, e0181960.	1.1	162
32	Mortality of HIV-Infected Patients Starting Antiretroviral Therapy in Sub-Saharan Africa: Comparison with HIV-Unrelated Mortality. PLoS Medicine, 2009, 6, e1000066.	3.9	161
33	Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. Lancet HIV,the, 2018, 5, e291-e300.	2.1	155
34	Lipodystrophy, Metabolic Disorders, and Human Immunodeficiency Virus Infection: Aquitaine Cohort, France, 1999. Clinical Infectious Diseases, 2000, 31, 1482-1487.	2.9	152
35	Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. Aids, 2008, 22, 2291-2302.	1.0	152
36	Twenty-four month efficacy of a maternal short-course zidovudine regimen to prevent mother-to-child transmission of HIV-1 in West Africa. Aids, 2002, 16, 631-641.	1.0	143

#	Article	IF	CITATIONS
37	Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. Aids, 2005, 19, 309-18.	1.0	143
38	Immunodeficiency at the Start of Combination Antiretroviral Therapy in Low-, Middle-, and High-Income Countries. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, e8-e16.	0.9	142
39	Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. Clinical Infectious Diseases, 2014, 58, 1312-1321.	2.9	140
40	Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. Aids, 2009, 23, 1867-1874.	1.0	136
41	Net survival of perinatally and postnatally HIV-infected children: a pooled analysis of individual data from sub-Saharan Africa. International Journal of Epidemiology, 2011, 40, 385-396.	0.9	135
42	Uptake of Home-Based HIV Testing, Linkage to Care, and Community Attitudes about ART in Rural KwaZulu-Natal, South Africa: Descriptive Results from the First Phase of the ANRS 12249 TasP Cluster-Randomised Trial. PLoS Medicine, 2016, 13, e1002107.	3.9	135
43	Coverage of Nevirapine-Based Services to Prevent Mother-to-Child HIV Transmission in 4 African Countries. JAMA - Journal of the American Medical Association, 2010, 304, 293.	3.8	131
44	Cognitive disorders in HIV-infected patients. Aids, 2013, 27, 391-400.	1.0	125
45	The Changing Incidence of AIDS Events in Patients Receiving Highly Active Antiretroviral Therapy. Archives of Internal Medicine, 2005, 165, 416.	4.3	124
46	Sexual and Reproductive Life of Women Informed of Their HIV Seropositivity: A Prospective Cohort Study in Burkina Faso. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 28, 367-372.	0.9	122
47	Tobacco Addiction and HIV Infection: Toward the Implementation of Cessation Programs. ANRS CO3 Aquitaine Cohort. AIDS Patient Care and STDs, 2007, 21, 458-468.	1.1	121
48	Acceptability of Routine HIV Testing ("Opt-Out") in Antenatal Services in Two Rural Districts of Zimbabwe. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 41, 514-520.	0.9	119
49	Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. Annals of Medicine, 2002, 34, 55-63.	1.5	118
50	Antiretroviral Treatment and Prevention of Peripartum and Postnatal HIV Transmission in West Africa: Evaluation of a Two-Tiered Approach. PLoS Medicine, 2007, 4, e257.	3.9	118
51	Concentrations of Tenofovir and Emtricitabine in Breast Milk of HIV-1-Infected Women in Abidjan, CoÌ,te d'Ivoire, in the ANRS 12109 TEmAA Study, Step 2. Antimicrobial Agents and Chemotherapy, 2011, 55, 1315-1317.	1.4	118
52	Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations Aquitaine Cohort, France, 1996-1998. Aids, 1999, 13, 115-151.	1.0	117
53	HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative pregnant women in Abidjan, Côte d'Ivoire: The ANRS 1236 study. Journal of Medical Virology, 2004, 74, 34-40.	2.5	117
54	Monitoring effectiveness of programmes to prevent mother-to-child HIV transmission in lower-income countries. Bulletin of the World Health Organization, 2008, 86, 57-62.	1.5	112

#	Article	IF	CITATIONS
55	Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. Neurology, 2014, 83, 134-141.	1.5	112
56	Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire. Aids, 2008, 22, 1815-1820.	1.0	110
57	HIV Prevention in Clinical Care Settings. JAMA - Journal of the American Medical Association, 2014, 312, 390.	3.8	109
58	Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a cluster randomised controlled trial. Trials, 2013, 14, 230.	0.7	105
59	Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. Clinical Infectious Diseases, 2018, 66, 893-903.	2.9	105
60	Predictors of Hypertension and Changes of Blood Pressure in HIV-Infected Patients. Antiviral Therapy, 2005, 10, 811-823.	0.6	103
61	Acceptability of voluntary HIV testing by pregnant women in developing countries. Aids, 1998, 12, 2489-2493.	1.0	100
62	Role of Uncontrolled HIV RNA Level and Immunodeficiency in the Occurrence of Malignancy in HIVâ€Infected Patients during the Combination Antiretroviral Therapy Era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clinical Infectious Diseases, 2009, 49, 1109-1116.	2.9	100
63	Mortality in Patients with HIV-1 Infection Starting Antiretroviral Therapy in South Africa, Europe, or North America: A Collaborative Analysis of Prospective Studies. PLoS Medicine, 2014, 11, e1001718.	3.9	100
64	Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration. BMC Medicine, 2016, 14, 61.	2.3	100
65	Tuberculosis after Initiation of Antiretroviral Therapy in Low-Income and High-Income Countries. Clinical Infectious Diseases, 2007, 45, 1518-1521.	2.9	98
66	Children Who Acquire HIV Infection Perinatally Are at Higher Risk of Early Death than Those Acquiring Infection through Breastmilk: A Meta-Analysis. PLoS ONE, 2012, 7, e28510.	1.1	98
67	Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis. Lancet HIV,the, 2015, 2, e271-e278.	2.1	98
68	What do the Universal Test and Treat trials tell us about the path to HIV epidemic control?. Journal of the International AIDS Society, 2020, 23, e25455.	1.2	96
69	Discordant Responses to Potent Antiretroviral Treatment in Previously Naive HIV-1-Infected Adults Initiating Treatment in Resource-Constrained Countries. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 45, 52-59.	0.9	94
70	HIV Status Disclosure and Retention in Care in HIV-Infected Adolescents on Antiretroviral Therapy (ART) in West Africa. PLoS ONE, 2012, 7, e33690.	1.1	94
71	Use of Antiretroviral Drugs to Prevent HIV-1 Transmission Through Breast-feeding: From Animal Studies to Randomized Clinical Trials. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 178-187.	0.9	93
72	The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. Aids, 2006, 20, 21-28.	1.0	92

#	Article	IF	CITATIONS
73	Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy. Aids, 2008, 22, 1417-1423.	1.0	92
74	Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy. Kidney International, 2011, 80, 302-309.	2.6	92
75	The Incidence of AIDS-Defining Illnesses at a Current CD4 Count ≥200 Cells/µL in the Post–Combination Antiretroviral Therapy Era. Clinical Infectious Diseases, 2013, 57, 1038-1047.	2.9	92
76	Effect of HIV-1 infection on pregnancy outcome in women in Kigali, Rwanda, 1992–1994. Aids, 1998, 12, 643-650.	1.0	91
77	Retention and mortality on antiretroviral therapy in sub‣aharan Africa: collaborative analyses of HIV treatment programmes. Journal of the International AIDS Society, 2018, 21, e25084.	1.2	91
78	Two-Year Morbidity–Mortality and Alternatives to Prolonged Breast-Feeding among Children Born to HIV-Infected Mothers in Côte d'Ivoire. PLoS Medicine, 2007, 4, e17.	3.9	89
79	Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events. Aids, 2013, 27, 407-415.	1.0	89
80	Diabetes Mellitus, Preexisting Coronary Heart Disease, and the Risk of Subsequent Coronary Heart Disease Events in Patients Infected With Human Immunodeficiency Virus. Circulation, 2009, 119, 805-811.	1.6	88
81	The Challenge of AIDS-Related Malignancies in Sub-Saharan Africa. PLoS ONE, 2010, 5, e8621.	1.1	88
82	Human papillomavirus and human immunodeficiency virus infections: relation with cervical dysplasia-neoplasia in African women. , 1998, 76, 480-486.		84
83	Growth of human immunodeficiency type 1-infected and uninfected children: a prospective cohort study in Kigali, Rwanda, 1988 to 1993. Pediatric Infectious Disease Journal, 1996, 15, 479-485.	1.1	83
84	Outcomes of Antiretroviral Therapy in Children in Asia and Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 208-219.	0.9	81
85	Comparative assessment of five trials of universal <scp>HIV</scp> testing and treatment in subâ€Saharan Africa. Journal of the International AIDS Society, 2018, 21, e25048.	1.2	81
86	Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Aids, 2000, 14, 971-978.	1.0	80
87	Prevention of mother to child transmission of HIV: evaluation of a pilot programme in a district hospital in rural Zimbabwe. BMJ: British Medical Journal, 2004, 329, 1147-1150.	2.4	80
88	Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France. Aids, 2008, 22, 457-468.	1.0	80
89	Universal Antiretroviral Therapy for Pregnant and Breastâ€Feeding HIVâ€1–Infected Women: Towards the Elimination of Motherâ€toâ€Child Transmission of HIVâ€1 in Resourceâ€Limited Settings. Clinical Infectious Diseases, 2009, 49, 1936-1945.	2.9	80
90	Low retention of HIVâ€infected patients on antiretroviral therapy in 11 clinical centres in West Africa. Tropical Medicine and International Health, 2010, 15, 34-42.	1.0	80

#	Article	IF	CITATIONS
91	The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13) Tj ETQq1 1 0.784	314 rgBT 1.3	Ölerlock 1
92	Pregnancy Outcomes in Women Exposed to Efavirenz and Nevirapine: An Appraisal of the leDEA West Africa and ANRS Databases, Abidjan, Côte d'Ivoire. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 183-187.	0.9	79
93	Contraceptive use, protected sexual intercourse and incidence of pregnancies among African HIV-infected women. DITRAME ANRS 049 Project, Abidjan 1995–2000. International Journal of STD and AIDS, 2002, 13, 462-468.	0.5	78
94	Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy. Tropical Medicine and International Health, 2009, 14, 1220-1225.	1.0	78
95	CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus–Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC). Clinical Infectious Diseases, 2017, 65, 959-966.	2.9	75
96	Epidemiology of Pertussis in a West African Community before and after Introduction of a Widespread Vaccination Program. American Journal of Epidemiology, 2002, 155, 891-896.	1.6	74
97	Implementing a rural programme of prevention of mother-to-child transmission of HIV in Zimbabwe: first 18 months of experience. Tropical Medicine and International Health, 2004, 9, 774-783.	1.0	73
98	Cohort Profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts. International Journal of Epidemiology, 2005, 34, 979-986.	0.9	72
99	Is there a difference in the efficacy of peripartum antiretroviral regimens in reducing mother-to-child transmission of HIV in Africa?. Aids, 2005, 19, 1865-1875.	1.0	72
100	Mortality after failure of antiretroviral therapy in subâ€Saharan Africa. Tropical Medicine and International Health, 2010, 15, 251-258.	1.0	71
101	Attitude of pregnant women towards HIV testing in Abidjan, Côte d'Ivoire and Bobo-Dioulasso, Burkina Faso. Aids, 1998, 12, 2337-2344.	1.0	70
102	Mother–to–Child Transmission of Human Immunodeficiency Virus Type 1 (HIV–1) and Its Determinants: A Cohort Study in Kigali, Rwanda. American Journal of Epidemiology, 1993, 137, 589-599.	1.6	69
103	Low Risk of Nevirapine Resistance Mutations in the Prevention of Motherâ€toâ€Child Transmission of HIVâ€1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Côte d'lvoire. Journal of Infectious Diseases, 2006, 193, 482-487.	1.9	68
104	Perinatal transmission of HIV-1. Aids, 1991, 5, 295-300.	1.0	66
105	Cost-Effectiveness of Preventing Loss to Follow-up in HIV Treatment Programs: A Côte d'Ivoire Appraisal. PLoS Medicine, 2009, 6, e1000173.	3.9	66
106	Pediatric Viral Human Immunodeficiency Virus Type 1 RNA Levels, Timing of Infection, and Disease Progression in African HIV-1-Infected Children. Pediatrics, 2003, 112, e289-e289.	1.0	65
107	Postnatal transmission of HIV-1 after a maternal short-course zidovudine peripartum regimen in West Africa. Aids, 2003, 17, 1493-1501.	1.0	65
108	High frequency of poor locomotor performance in HIV-infected patients. Aids, 2011, 25, 797-805.	1.0	65

#	Article	IF	CITATIONS
109	Prognostic Importance of Anaemia in HIV Type-1-Infected Patients Starting Antiretroviral Therapy: Collaborative Analysis of Prospective Cohort Studies. Antiviral Therapy, 2008, 13, 959-967.	0.6	65
110	18-Month mortality and perinatal exposure to zidovudine in West Africa. Aids, 2001, 15, 771-779.	1.0	64
111	Early diagnosis of paediatric HIV-1 infection among African breast-fed children using a quantitative plasma HIV RNA assay. Aids, 2001, 15, 1849-1856.	1.0	64
112	Cohort Profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). International Journal of Epidemiology, 2014, 43, 691-702.	0.9	64
113	Estimating the efficacy of interventions to prevent mother-to-child transmission of HIV in breast-feeding populations: development of a consensus methodology. Statistics in Medicine, 2001, 20, 3539-3556.	0.8	63
114	Field Evaluation of a Rapid Human Immunodeficiency Virus (HIV) Serial Serologic Testing Algorithm for Diagnosis and Differentiation of HIV Type 1 (HIV-1), HIV-2, and Dual HIV-1-HIV-2 Infections in West African Pregnant Women. Journal of Clinical Microbiology, 2004, 42, 4147-4153.	1.8	63
115	Validation and Comparison of Simple Noninvasive Indexes for Predicting Liver Fibrosis in HIV-HCV-Coinfected Patients: ANRS CO3 Aquitaine Cohort. American Journal of Gastroenterology, 2008, 103, 1973-1980.	0.2	63
116	International epidemiology databases to evaluate AIDS (IeDEA) in sub-Saharan Africa, 2012–2019. BMJ Open, 2020, 10, e035246.	0.8	63
117	REPORT OF A WORKSHOP FOR CLINICAL RESEARCH. Pediatric Infectious Disease Journal, 1998, 17, 581-586.	1.1	63
118	Access to HIV care in the context of universal test and treat: challenges within the ANRS 12249 TasP clusterâ€randomized trial in rural South Africa. Journal of the International AIDS Society, 2016, 19, 20913.	1.2	62
119	Changes in CD4+ cell count and the risk of opportunistic infection or death after highly active antiretroviral treatment. Aids, 1998, 12, 2313-2320.	1.0	61
120	Duration, Pattern of Breastfeeding and Postnatal Transmission of HIV: Pooled Analysis of Individual Data from West and South African Cohorts. PLoS ONE, 2009, 4, e7397.	1.1	61
121	Population Pharmacokinetics of Emtricitabine in Human Immunodeficiency Virus Type 1-Infected Pregnant Women and Their Neonates. Antimicrobial Agents and Chemotherapy, 2009, 53, 1067-1073.	1.4	61
122	Effect of Cytomegalovirus-Induced Immune Response, Self Antigen–Induced Immune Response, and Microbial Translocation on Chronic Immune Activation in Successfully Treated HIV Type 1–Infected Patients: The ANRS CO3 Aquitaine Cohort. Journal of Infectious Diseases, 2013, 207, 622-627.	1.9	61
123	Determinants of delayed diagnosis of HIV infection in France, 1993–1995. Aids, 1998, 12, 795-800.	1.0	59
124	Early mixed feeding and breastfeeding beyond 6 months increase the risk of postnatal HIV transmission: ANRS 1201/1202 Ditrame Plus, Abidjan, Côte d'Ivoire. Preventive Medicine, 2008, 47, 27-33.	1.6	59
125	Factors Associated with the Occurrence of AIDS-Related Non-Hodgkin Lymphoma in the Era of Highly Active Antiretroviral Therapy: Aquitaine Cohort, France. Clinical Infectious Diseases, 2006, 42, 411-417.	2.9	58
126	Couple-oriented prenatal HIV counseling for HIV primary prevention: an acceptability study. BMC Public Health, 2010, 10, 197.	1.2	58

#	Article	IF	CITATIONS
127	Cervical cancer screening by visual inspection in Côte d'Ivoire, operational and clinical aspects according to HIV status. BMC Public Health, 2012, 12, 237.	1.2	58
128	CD4+ T-Lymphocyte Counts in HIV Infection. Journal of Acquired Immune Deficiency Syndromes, 1997, 14, 361-363.	0.3	57
129	Seroincidence of HIV-1 infection in African women of reproductive age. Aids, 1994, 8, 983-986.	1.0	56
130	Is hepatitis C virus co-infection associated with survival in HIV-infected patients treated by combination antiretroviral therapy?. Aids, 2002, 16, 1357-1362.	1.0	56
131	Occult Hepatitis B Virus Infection in HIV-Infected Patients with Isolated Antibodies to Hepatitis B Core Antigen: Aquitaine Cohort, 2002-2003. Clinical Infectious Diseases, 2005, 40, 750-753.	2.9	55
132	Do Tests Devised to Detect Recent HIV-1 Infection Provide Reliable Estimates of Incidence in Africa?. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 45, 115-122.	0.9	53
133	What Will It Take to Eliminate Pediatric HIV? Reaching WHO Target Rates of Mother-to-Child HIV Transmission in Zimbabwe: A Model-Based Analysis. PLoS Medicine, 2012, 9, e1001156.	3.9	53
134	Squamous intraepithelial lesions of the cervix, invasive cervical carcinoma, and immunosuppression induced by human immunodeficiency virus in africa. Cancer, 1998, 82, 2401-2408.	2.0	52
135	12-month mortality and loss-to-program in antiretroviral-treated children: The IeDEA pediatric West African Database to evaluate AIDS (pWADA), 2000-2008. BMC Public Health, 2011, 11, 519.	1.2	52
136	Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. Lancet HIV,the, 2015, 2, e335-e343.	2.1	52
137	Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study. Clinical Infectious Diseases, 2016, 62, 1571-1577.	2.9	52
138	All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus–coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13–HEPAVIH Cohort. Clinical Infectious Diseases, 2016, 63, 763-770.	2.9	52
139	Alcohol use and nonâ€adherence to antiretroviral therapy in HIVâ€infected patients in West Africa. Addiction, 2010, 105, 1416-1421.	1.7	51
140	Associations between immune depression and cardiovascular events in HIV infection. Aids, 2013, 27, 2735-2748.	1.0	51
141	Prospective cohort study of the effect of pregnancy on the progression of human immunodeficiency virus infection. Obstetrics and Gynecology, 1995, 86, 886-891.	1.2	50
142	Disease patterns and causes of death of hospitalized HIVâ€positive adults in West Africa: a multicountry survey in the antiretroviral treatment era. Journal of the International AIDS Society, 2014, 17, 18797.	1.2	50
143	Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons. Aids, 2016, 30, 1731-1743.	1.0	50
144	Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antiviral Therapy, 2008, 13, 959-67.	0.6	50

#	Article	IF	CITATIONS
145	Postnatal transmission of HIV-1 associated with breast abscess. Lancet, The, 1992, 339, 1490-1491.	6.3	49
146	Complementary Feeding Adequacy in Relation to Nutritional Status Among Early Weaned Breastfed Children Who Are Born to HIV-Infected Mothers: ANRS 1201/1202 Ditrame Plus, Abidjan, Cote d'Ivoire. Pediatrics, 2006, 117, e701-e710.	1.0	49
147	Bacterial Pneumonia among HIV-Infected Patients: Decreased Risk After Tobacco Smoking Cessation. ANRS CO3 Aquitaine Cohort, 2000–2007. PLoS ONE, 2010, 5, e8896.	1.1	49
148	Impact of Next-generation Sequencing Defined Human Immunodeficiency Virus Pretreatment Drug Resistance on Virological Outcomes in the ANRS 12249 Treatment-as-Prevention Trial. Clinical Infectious Diseases, 2019, 69, 207-214.	2.9	48
149	Effect of Gender, Age, Transmission Category, and Antiretroviral Therapy on the Progression of Human Immunodeficiency Virus Infection Using Multistate Markov Models. Epidemiology, 1998, 9, 605-612.	1.2	47
150	Cost-effectiveness of World Health Organization 2010 Guidelines for Prevention of Mother-to-Child HIV Transmission in Zimbabwe. Clinical Infectious Diseases, 2013, 56, 430-446.	2.9	47
151	Increasing HIV testing among male partners. Aids, 2013, 27, 1167-1177.	1.0	47
152	Factors associated with antiretroviral treatment initiation amongst HIV-positive individuals linked to care within a universal test and treat programme: early findings of the ANRS 12249 TasP trial in rural South Africa. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2016, 28, 39-51.	0.6	47
153	Acceptability and uptake of a package to prevent mother-to-child transmission using rapid HIV testing in Abidjan, Côte d'Ivoire. Aids, 2004, 18, 697-700.	1.0	46
154	The case for an HIV cure and how to get there. Lancet HIV,the, 2021, 8, e51-e58.	2.1	46
155	Increases in CD3+CD4-CDS- T Lymphocytes in AIDS Patients with Disseminated Mycobacterium avium-intracellulare Complex Infection. Journal of Infectious Diseases, 1996, 174, 969-976.	1.9	45
156	Population Pharmacokinetics of Nevirapine in HIV-1-Infected Pregnant Women and Their Neonates. Antimicrobial Agents and Chemotherapy, 2011, 55, 331-337.	1.4	45
157	Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients – French ANRS CO13 HEPAVIH cohort. Journal of Hepatology, 2017, 67, 23-31.	1.8	45
158	HIV infection, malaria, and pregnancy: a prospective cohort study in Kigali, Rwanda American Journal of Tropical Medicine and Hygiene, 2002, 66, 56-60.	0.6	45
159	A cohort study of factors associated with failure to return for HIV post-test counselling in pregnant women. Aids, 1996, 10, 69-76.	1.0	44
160	Beneficial Effects of Offering Prenatal HIV Counselling and Testing on Developing a HIV Preventive Attitude among Couples. Abidjan, 2002–2005. AIDS and Behavior, 2009, 13, 348-355.	1.4	44
161	Evaluation of the impact of a breast cancer awareness program in rural Ghana: A crossâ€sectional survey. International Journal of Cancer, 2014, 134, 913-924.	2.3	44
162	THE EPIDEMIOLOGY OF MEASLES IN A PARTIALLY VACCINATED POPULATION IN AN AFRICAN CITY: IMPLICATIONS FOR IMMUNIZATION PROGRAMS. American Journal of Epidemiology, 1988, 127, 171-178.	1.6	43

#	Article	IF	CITATIONS
163	Weight Loss and Body Mass Index as Predictors of HIV Disease Progression to AIDS in Adults. Aquitaine Cohort, France, 1985–1997. Journal of the American College of Nutrition, 2001, 20, 609-615.	1.1	43
164	Field acceptability and effectiveness of the routine utilization of zidovudine to reduce mother-to-child transmission of HIV-1 in West Africa. Aids, 2002, 16, 2323-2328.	1.0	43
165	Maternal 12-Month Response to Antiretroviral Therapy following Prevention of Mother-to-Child Transmission of HIV Type 1, Ivory Coast, 2003- 2006. Clinical Infectious Diseases, 2008, 46, 611-621.	2.9	43
166	The Spectrum of Cancers in West Africa: Associations with Human Immunodeficiency Virus. PLoS ONE, 2012, 7, e48108.	1.1	43
167	Genotypic resistance profiles of HIV-2-treated patients in West Africa. Aids, 2014, 28, 1161-1169.	1.0	43
168	Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. International Journal of Epidemiology, 2016, 45, 2038-2049.	0.9	43
169	Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antiviral Therapy, 2005, 10, 811-23.	0.6	43
170	Rapid Change in the Use of Antiretroviral Agents and Improvement in a Population of HIV-Infected Patients: France, 1995 to 1997. Journal of Acquired Immune Deficiency Syndromes, 1998, 18, 358-364.	0.3	42
171	Preventing mother-to-child transmission of HIV-1 in Africa in the year 2000. Aids, 2000, 14, 1017-1026.	1.0	42
172	Effect of Perinatal Zidovudine Prophylaxis on the Evolution of Cellâ€Free HIVâ€1 RNA in Breast Milk and on Postnatal Transmission. Journal of Infectious Diseases, 2004, 190, 1422-1428.	1.9	42
173	Altered Vaginal Microbiota Are Associated With Perinatal Mother-to-Child Transmission of HIV in African Women From Burkina Faso. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, 299-306.	0.9	42
174	Decline in locomotor functions over time in HIV-infected patients. Aids, 2014, 28, 1441-1449.	1.0	42
175	Prevalence and Evolution of Low Frequency HIV Drug Resistance Mutations Detected by Ultra Deep Sequencing in Patients Experiencing First Line Antiretroviral Therapy Failure. PLoS ONE, 2014, 9, e86771.	1.1	42
176	Evaluation and simplification of the World Health Organization clinical case definition for paediatric AIDS. Aids, 1989, 3, 221-226.	1.0	41
177	Children and HIV/AIDS: from research to policy and action in resource-limited settings. Aids, 2008, 22, 797-805.	1.0	41
178	WHO 2010 Guidelines for Prevention of Mother-to-Child HIV Transmission in Zimbabwe: Modeling Clinical Outcomes in Infants and Mothers. PLoS ONE, 2011, 6, e20224.	1.1	41
179	Loss of Maternal Measles Antibody during Infancy in an African City. International Journal of Epidemiology, 1989, 18, 264-268.	0.9	40
180	Acceptability of Exclusive Breast-Feeding With Early Cessation to Prevent HIV Transmission Through Breast Milk, ANRS 1201/1202 Ditrame Plus, Abidjan, Côte d'Ivoire. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 600-608.	0.9	40

#	Article	IF	CITATIONS
181	Delayed HIV diagnosis and initiation of antiretroviral therapy. Aids, 2014, 28, 2297-2306.	1.0	39
182	Intimate partner sexual and physical violence among women in Togo, West Africa: Prevalence, associated factors, and the specific role of HIV infection. Global Health Action, 2014, 7, 23456.	0.7	39
183	Impact of the Ebola epidemic on general and HIV care in Macenta, Forest Guinea, 2014. Aids, 2015, 29, 1883-1887.	1.0	39
184	Mortality Associated With Discordant Responses to Antiretroviral Therapy in Resource-Constrained Settings. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 53, 70-77.	0.9	38
185	Plasma and Intracellular Tenofovir Pharmacokinetics in the Neonate (ANRS 12109 Trial, Step 2). Antimicrobial Agents and Chemotherapy, 2011, 55, 2961-2967.	1.4	38
186	Insulin resistance is associated with a higher risk of hepatocellular carcinoma in cirrhotic HIV/HCV-co-infected patients: Results from ANRS CO13 HEPAVIH. Journal of Hepatology, 2012, 56, 862-868.	1.8	38
187	Increased nonâ€ <scp>AIDS</scp> mortality among persons with <scp>AIDS</scp> â€defining events after antiretroviral therapy initiation. Journal of the International AIDS Society, 2018, 21, e25031.	1.2	38
188	HIV treatment eligibility expansion and timely antiretroviral treatment initiation following enrollment in HIV care: A metaregression analysis of programmatic data from 22 countries. PLoS Medicine, 2018, 15, e1002534.	3.9	38
189	The Financial Burden of Morbidity in HIV-Infected Adults on Antiretroviral Therapy in Côte d'Ivoire. PLoS ONE, 2010, 5, e11213.	1.1	38
190	Non-Acquired Immune Deficiency Syndrome-Defining Malignancies in a Hospital-Based Cohort of Human Immunodeficiency Virus-Infected Patients: Bordeaux, France, 1985-1991. Journal of the National Cancer Institute, 1992, 84, 1593-1595.	3.0	37
191	Impaired fertility in HIV-1-infected pregnant women: a clinic-based survey in Abidjan, Côte d'Ivoire, 1997. Aids, 1999, 13, 517-521.	1.0	37
192	Variation of CD4 Count and Percentage during Pregnancy and after Delivery: Implications for HAART Initiation in Resource-Limited Settings. AIDS Research and Human Retroviruses, 2007, 23, 1469-1474.	0.5	37
193	Virological Outcomes of Second-line Protease Inhibitor–Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis. Clinical Infectious Diseases, 2017, 64, 1006-1016.	2.9	37
194	Health Facility Characteristics and Their Relationship to Coverage of PMTCT of HIV Services across Four African Countries: The PEARL Study. PLoS ONE, 2012, 7, e29823.	1.1	37
195	18-Month Effectiveness of Short-Course Antiretroviral Regimens Combined with Alternatives to Breastfeeding to Prevent HIV Mother-to-Child Transmission. PLoS ONE, 2008, 3, e1645.	1.1	36
196	Effect of age on immunological response in the first year of antiretroviral therapy in HIV-1-infected adults in West Africa. Aids, 2012, 26, 951-957.	1.0	36
197	Antiretroviral therapy response among HIV-2 infected patients: a systematic review. BMC Infectious Diseases, 2014, 14, 461.	1.3	36
198	Prognostic factors after non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus. Cancer, 2000, 88, 1696-1702.	2.0	35

#	Article	IF	CITATIONS
199	HBV or HCV Coinfections and Risk of Myocardial Infarction in HIV-Infected Individuals: The D:A:D Cohort Study. Antiviral Therapy, 2010, 15, 1077-1086.	0.6	35
200	Continuum in <scp>HIV</scp> care from entry to <scp>ART</scp> initiation in rural <scp>K</scp> wa <scp>Z</scp> uluâ€ <scp>N</scp> atal, <scp>S</scp> outh <scp>A</scp> frica. Tropical Medicine and International Health, 2014, 19, 680-689.	1.0	35
201	Chorioamnionitis and Pregnancy Outcome in HIV-Infected African Women. Journal of Acquired Immune Deficiency Syndromes, 1998, 18, 293-298.	0.3	34
202	Estimating the Efficacy of Interventions to Prevent Mother-to-Child Transmission of Human Immunodeficiency Virus in Breastfeeding Populations: Comparing Statistical Methods. American Journal of Epidemiology, 2003, 158, 596-605.	1.6	34
203	Presence of Key Drug Resistance Mutations in Isolates from Untreated Patients of Abidjan, Côte d'Ivoire: ANRS 1257 Study. AIDS Research and Human Retroviruses, 2003, 19, 713-717.	0.5	34
204	Change in atherosclerosis progression in HIV-infected patients: ANRS Aquitaine Cohort, 1999–2004. Aids, 2005, 19, 729-731.	1.0	34
205	Impact of Nevirapine (NVP) Plasma Concentration on Selection of Resistant Virus in Mothers Who Received Single-Dose NVP To Prevent Perinatal Human Immunodeficiency Virus Type 1 Transmission and Persistence of Resistant Virus in Their Infected Children. Antimicrobial Agents and Chemotherapy, 2007. 51. 896-901.	1.4	34
206	Severe morbidity and mortality in untreated HIV-infected children in a paediatric care programme in Abidjan, Côte d'Ivoire, 2004-2009. BMC Infectious Diseases, 2011, 11, 182.	1.3	34
207	The impact of population dynamics on the population <scp>HIV</scp> care cascade: results from the <scp>ANRS</scp> 12249 Treatment as Prevention trial in rural KwaZuluâ€Natal (South Africa). Journal of the International AIDS Society, 2018, 21, e25128.	1.2	34
208	Universal test and treat is not associated with subâ€optimal antiretroviral therapy adherence in rural South Africa: the ANRS 12249 TasP trial. Journal of the International AIDS Society, 2018, 21, e25112.	1.2	34
209	Squamous intraepithelial lesions of the cervix, invasive cervical carcinoma, and immunosuppression induced by human immunodeficiency virus in africa. , 1998, 82, 2401.		34
210	Maternal plasma viral load, zidovudine and mother-to-child transmission of HIV-1 in Africa: DITRAME ANRS 049a trial. Aids, 2001, 15, 517-522.	1.0	33
211	Prognostic Factors of Combined Viral Load and CD4+ Cell Count Responses Under Triple Antiretroviral Therapy, Aquitaine Cohort, 1996–1998. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 27, 161-167.	0.9	33
212	Vaccines to prevent transmission of HIV-1 via breastmilk: scientific and logistical priorities. Lancet, The, 2006, 368, 511-521.	6.3	33
213	Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort. Journal of Antimicrobial Chemotherapy, 2009, 63, 1251-1255.	1.3	33
214	Antiretroviral treatment and quality of life in Africans living with HIV: 12â€month followâ€up in Burkina Faso. Journal of the International AIDS Society, 2013, 16, 18867.	1.2	33
215	HIV infection, viral hepatitis and liver fibrosis among prison inmates in West Africa. BMC Infectious Diseases, 2016, 16, 249.	1.3	33
216	Alcohol use, viral hepatitis and liver fibrosis among HIVâ€positive persons in West Africa: a crossâ€sectional study. Journal of the International AIDS Society, 2017, 20, 21424.	1.2	33

#	Article	IF	CITATIONS
217	Women and HIV infection. Aids, 1992, 6, 1187-1194.	1.0	32
218	Mortality and survival patterns of people living with HIV-2. Current Opinion in HIV and AIDS, 2016, 11, 537-544.	1.5	32
219	Characteristics of HIV-2 and HIV-1/HIV-2 Dually Seropositive Adults in West Africa Presenting for Care and Antiretroviral Therapy: The leDEA-West Africa HIV-2 Cohort Study. PLoS ONE, 2013, 8, e66135.	1.1	32
220	First-year lymphocyte T CD4+ response to antiretroviral therapy according to the HIV type in the IeDEA West Africa collaboration. Aids, 2010, 24, 1043-1050.	1.0	31
221	Trends in hepatitis B virus testing practices and management in HIV clinics across sub-Saharan Africa. BMC Infectious Diseases, 2017, 17, 706.	1.3	31
222	Incidence of hepatocellular carcinoma in HIV/HBV-coinfected patients on tenofovir therapy: Relevance for screening strategies. Journal of Hepatology, 2019, 71, 274-280.	1.8	31
223	Herpes Zoster and Human Immunodeficiency Virus Infection: A Cohort Study of 101 Coinfected Patients. Journal of Infectious Diseases, 1993, 168, 245-245.	1.9	30
224	Cost-effectiveness and cost-benefit in the prevention of mother-to-child transmission of HIV in developing countries. Aids, 1998, 12, 1571-1580.	1.0	30
225	Hepatitis B and C infections, human immunodeficiency virus and other sexually transmitted infections among women of childbearing age in Côte d'Ivoire, West Africa. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2001, 95, 493-496.	0.7	30
226	Causes and empirical treatment of fever in HIV-infected adult outpatients, Abidjan, Côte d'Ivoire. Aids, 2002, 16, 909-918.	1.0	30
227	Acceptability of Formula-Feeding to Prevent HIV Postnatal Transmission, Abidjan, Côte d'Ivoire. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 44, 77-86.	0.9	30
228	Cohort Profile: The Paediatric Antiretroviral Treatment Programmes in Lower-Income Countries (KIDS-ART-LINC) Collaboration. International Journal of Epidemiology, 2008, 37, 474-480.	0.9	30
229	Retention in Care Trajectories of HIV-Positive Individuals Participating in a Universal Test-and-Treat Program in Rural South Africa (ANRS 12249 TasP Trial). Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 375-385.	0.9	30
230	Serum Lactate Levels in Infants Exposed Peripartum to Antiretroviral Agents to Prevent Mother-to-Child Transmission of HIV: Agence Nationale de Recherches Sur le SIDA et les Hepatites Virales 1209 Study, Abidjan, Ivory Coast. Pediatrics, 2006, 118, e1071-e1077.	1.0	29
231	HIV-1 Antiretroviral Drug Resistance in Recently Infected Patients in Abidjan, Côte d'Ivoire: A 4-Year Survey, 2002–2006. AIDS Research and Human Retroviruses, 2007, 23, 1155-1160.	0.5	29
232	Transmission Rates in Consecutive Pregnancies Exposed to Single-Dose Nevirapine in Soweto, South Africa and Abidjan, Côte d'Ivoire. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 45, 206-209.	0.9	29
233	Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1. Aids, 2009, 23, 825-833.	1.0	29
234	Cervical cancer prevention in reproductive health services: knowledge, attitudes and practices of midwives in Côte d'Ivoire, West Africa. BMC Health Services Research, 2014, 14, 165.	0.9	29

#	Article	IF	CITATIONS
235	Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 97-107.	0.9	29
236	Prevalence of and Factors Associated With Hepatic Steatosis in Patients Coinfected With Hepatitis C Virus and HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 45, 168-173.	0.9	28
237	Participation of traditional birth attendants in prevention of mother-to-child transmission of HIV services in two rural districts in Zimbabwe: a feasibility study. BMC Public Health, 2008, 8, 401.	1.2	28
238	Influence of Geographical Origin and Ethnicity on Mortality in Patients on Antiretroviral Therapy in Canada, Europe, and the United States. Clinical Infectious Diseases, 2013, 56, 1800-1809.	2.9	28
239	Retention in care prior to antiretroviral treatment eligibility in sub-Saharan Africa: a systematic review of the literature. BMJ Open, 2015, 5, e006927.	0.8	28
240	Contribution of Maternal Antiretroviral Therapy and Breastfeeding to 24-Month Survival in Human Immunodeficiency Virus-Exposed Uninfected Children: An Individual Pooled Analysis of African and Asian Studies. Clinical Infectious Diseases, 2018, 66, 1668-1677.	2.9	28
241	Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Coâ€infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or Endâ€Stage Liver Disease as Compared to HCV Monoâ€infected Patients. Hepatology, 2019, 70, 939-954.	3.6	28
242	Clinical and Biological Evolution of HIV-1 Seroconverters in Abidjan, Côte d'Ivoire, 1997–2000. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 29, 149-157.	0.9	27
243	Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Côte d'Ivoire. BMC Infectious Diseases, 2010, 10, 188.	1.3	27
244	Interventions to improve the performance of HIV health systems for treatment-as-prevention in sub-Saharan Africa. Current Opinion in HIV and AIDS, 2012, 7, 140-150.	1.5	27
245	AIDS and non-AIDS severe morbidity associated with hospitalizations among HIV-infected patients in two regions with universal access to care and antiretroviral therapy, France and Brazil, 2000–2008: hospital-based cohort studies. BMC Infectious Diseases, 2014, 14, 278.	1.3	27
246	Progression to WHO criteria for starting antiretroviral therapy in a 7-year cohort of adult HIV-1 seroconverters in Abidjan, Cote d'Ivoire. Bulletin of the World Health Organization, 2007, 85, 116-123.	1.5	27
247	Difference in Absolute CD4+ Count According to CD4 Percentage between Asian and Caucasian HIV-Infected Patients. Journal of AIDS & Clinical Research, 2010, 01, 1-4.	0.5	27
248	Estimating the incubation period of paediatric AIDS in Rwanda. Aids, 1992, 6, 1515-1520.	1.0	26
249	Avascular Necrosis in HIVâ€Infected Patients: A Caseâ€Control Study from the Aquitaine Cohort, 1997–2002, France. Clinical Infectious Diseases, 2005, 40, 1188-1193.	2.9	26
250	Interpretation of Genotype and Pharmacokinetics for Resistance to Fosamprenavir-Ritonavir-Based Regimens in Antiretroviral-Experienced Patients. Antimicrobial Agents and Chemotherapy, 2007, 51, 1473-1480.	1.4	26
251	Burden of <scp>HIV</scp> and hepatitis C coâ€infection: the changing epidemiology of hepatitis C in <scp>HIV</scp> â€infected patients in France. Liver International, 2015, 35, 65-70.	1.9	26
252	High prevalence of binge drinking among people living with HIV in four African countries. Journal of the International AIDS Society, 2018, 21, e25202.	1.2	26

#	Article	IF	CITATIONS
253	Primary HIV-1 drug resistance in Abidjan (Côte d'Ivoire): a genotypic and phenotypic study. Aids, 2002, 16, 488-491.	1.0	26
254	Antiretroviral Therapy and Sustained Virological Response to HCV Therapy are Associated with Slower Liver Fibrosis Progression in HIV–HCV-Coinfected Patients: Study from the Anrs Co 13 Hepavih Cohort. Antiviral Therapy, 2012, 17, 1335-1343.	0.6	25
255	Reâ€testing and misclassification of HIVâ€2 and HIVâ€1&2 dually reactive patients among the HIVâ€2 cohort of The West African Database to evaluate AIDS collaboration. Journal of the International AIDS Society, 2014, 17, 19064.	t 1.2	25
256	Cancer and HIV infection in referral hospitals from four West African countries. Cancer Epidemiology, 2015, 39, 1060-1065.	0.8	25
257	Pitfalls of practicing cancer epidemiology in resource-limited settings: the case of survival and loss to follow-up after a diagnosis of Kaposi's sarcoma in five countries across sub-Saharan Africa. BMC Cancer, 2016, 16, 65.	1.1	25
258	Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients. Journal of Hepatology, 2017, 67, 1157-1167.	1.8	25
259	Interaction between HIV-1 and HCV infections: towards a new entity?. Journal of Antimicrobial Chemotherapy, 2004, 53, 936-946.	1.3	24
260	Tobacco smoking and chewing as risk factors for multiple human papillomavirus infections and cervical squamous intraepithelial lesions in two countries (Côte d'Ivoire and Finland) with different tobacco exposure. Cancer Causes and Control, 2009, 20, 163-170.	0.8	24
261	Derivation of parameters used in Spectrum for eligibility for antiretroviral therapy and survival on antiretroviral therapy. Sexually Transmitted Infections, 2010, 86, ii28-ii34.	0.8	24
262	Measuring Coverage in MNCH: Population HIV-Free Survival among Children under Two Years of Age in Four African Countries. PLoS Medicine, 2013, 10, e1001424.	3.9	24
263	Oral lesions among <scp>HIV</scp> â€infected children on antiretroviral treatment in <scp>W</scp> est <scp>A</scp> frica. Tropical Medicine and International Health, 2014, 19, 246-255.	1.0	24
264	Diagnosis and clinical outcomes of extrapulmonary tuberculosis in antiretroviral therapy programmes in low―and middleâ€income countries: a multicohort study. Journal of the International AIDS Society, 2019, 22, e25392.	1.2	24
265	Diabetes and cognitive decline in a French cohort of patients infected with HIV-1. Neurology, 2015, 85, 1065-1073.	1.5	23
266	Hepatitis B treatment eligibility in West Africa: Uncertainties and need for prospective cohort studies. Liver International, 2017, 37, 1116-1121.	1.9	23
267	Pravastatin in HIV-Infected Patients Treated with Protease Inhibitors: A Placebo-Controlled Randomized Study. HIV Clinical Trials, 2007, 8, 53-60.	2.0	22
268	Coverage of intermittent prevention treatment with sulphadoxine-pyrimethamine among pregnant women and congenital malaria in Côte d'Ivoire. Malaria Journal, 2011, 10, 105.	0.8	22
269	When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 214-221.	0.9	22
270	Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. International Journal of Epidemiology, 2017, 46, dyw211.	0.9	22

#	Article	IF	CITATIONS
271	Eliminating postnatal HIV transmission in high incidence areas: need for complementary biomedical interventions. Lancet, The, 2021, 397, 1316-1324.	6.3	22
272	Effectiveness of Multidrug Antiretroviral Regimens to Prevent Mother-to-Child Transmission of HIV-1 in Routine Public Health Services in Cameroon. PLoS ONE, 2010, 5, e10411.	1.1	22
273	HIV drugs for treatment, and for prevention. Lancet, The, 2010, 375, 2056-2057.	6.3	21
274	Very High Concentrations of Active Intracellular Phosphorylated Emtricitabine in Neonates (ANRS) Tj ETQq0 0 0	rgBT /Ove 1.4	rlock 10 Tf 50
275	Plasma HIV-2 RNA According to CD4 Count Strata among HIV-2-Infected Adults in the leDEA West Africa Collaboration. PLoS ONE, 2015, 10, e0129886.	1.1	21
276	Cannabis Use and Reduced Risk of Insulin Resistance in HIV-HCV Infected Patients: A Longitudinal Analysis (ANRS CO13 HEPAVIH). Clinical Infectious Diseases, 2015, 61, 40-48.	2.9	21
277	Haematological characteristics and HIV status of pregnant women in Abidjan, Côte d'Ivoire, 1995–1996. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1999, 93, 419-422.	0.7	20
278	Incidence and Risk Factors for Severe Bacterial Infections in People Living with HIV. ANRS CO3 Aquitaine Cohort, 2000–2012. PLoS ONE, 2016, 11, e0152970.	1.1	20
279	Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. Open Forum Infectious Diseases, 2016, 3, ofw009.	0.4	20
280	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. Clinical Infectious Diseases, 2016, 63, ciw519.	2.9	20
281	Longitudinal Analysis of the Associations between Antiretroviral Therapy, Viraemia and Immunosuppression with Lipid Levels: The D:A:D Study. Antiviral Therapy, 2016, 21, 495-506.	0.6	20
282	Physical function, grip strength and frailty in people living with <scp>HIV</scp> in sub aharan Africa: systematic review. Tropical Medicine and International Health, 2017, 22, 516-525.	1.0	20
283	Are European HIV cohort data within EuroCoord representative of the diagnosed HIV population?. Aids, 2019, 33, 133-143.	1.0	20
284	To what extent could performance-based schemes help increase the effectiveness of prevention of mother-to-child transmission of HIV (PMTCT) programs in resource-limited settings? a summary of the published evidence. BMC Public Health, 2010, 10, 702.	1.2	19
285	HIV-induced immune deficiency is associated with a higher risk of hepatocarcinoma, ANRS CO3 Aquitaine Cohort, France, 1998–2008. Journal of Hepatology, 2011, 55, 1058-1062.	1.8	19
286	Association between elevated coffee consumption and daily chocolate intake with normal liver enzymes in HIV-HCV infected individuals: Results from the ANRS CO13 HEPAVIH cohort study. Journal of Hepatology, 2014, 60, 46-53.	1.8	19
287	Change of treatment guidelines and evolution of ART initiation in rural South Africa: data of a large HIV care and treatment programme. BMC Infectious Diseases, 2015, 15, 452.	1.3	19
288	Time-Updated CD4+ T Lymphocyte Count and HIV RNA as Major Markers of Disease Progression in Naive HIV-1-Infected Patients Treated With a Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 33, 380-386.	0.9	18

#	Article	IF	CITATIONS
289	Estimating incidence of HIV infection in childbearing age African women using serial prevalence data from antenatal clinics. Statistics in Medicine, 2007, 26, 320-335.	0.8	18
290	Hepatitis B virus genotypes : a retrospective survey in Southwestern France, 1999-2004. Gastroenterologie Clinique Et Biologique, 2007, 31, 1088-1094.	0.9	18
291	Does short-term virologic failure translate to clinical events in antiretroviral-naÃ ⁻ ve patients initiating antiretroviral therapy in clinical practice?. Aids, 2008, 22, 2481-2492.	1.0	18
292	Effect of sex and age on outcomes among HIV-2-infected patients starting antiretroviral therapy in West Africa. Aids, 2016, 30, 2707-2714.	1.0	18
293	No significant effect of cannabis use on the count and percentage of circulating CD4 Tâ€cells in HIVâ€HCV coâ€infected patients (ANRS CO13â€HEPAVIH French cohort). Drug and Alcohol Review, 2017, 36, 227-238.	1.1	18
294	Evaluation of 2 techniques of HIV pre-test counselling for pregnant women in West Africa. International Journal of STD and AIDS, 1999, 10, 199-201.	0.5	17
295	Gender differences in HIV-positive persons in use of cardiovascular disease-related interventions: D:A:D study. Journal of the International AIDS Society, 2014, 17, 19516.	1.2	17
296	Switch to Rilpivirine/Emtricitabine/Tenofovir Single-Tablet Regimen of Human Immunodeficiency Virus-1 RNA-Suppressed Patients, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO3 Aquitaine Cohort, 2012–2014. Open Forum Infectious Diseases, 2015, 2, ofv018.	0.4	17
297	CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study. Journal of Antimicrobial Chemotherapy, 2017, 72, 2869-2878.	1.3	17
298	Prevalence of hepatitis B and delta according to HIV-type: a multi-country cross-sectional survey in West Africa. BMC Infectious Diseases, 2017, 17, 466.	1.3	17
299	Lipodystrophy in HIV-1-infected patients. Lancet, The, 1999, 354, 867-868.	6.3	16
300	Decrease of human immunodeficiency virus prevalence in antenatal clinics in Abidjan, Côte d'Ivoire, 1995–2002. International Journal of STD and AIDS, 2006, 17, 57-60.	0.5	16
301	Pharmacovigilance for antiretroviral drugs in Africa: lessons from a study in Abidjan, Cote d'Ivoire. Pharmacoepidemiology and Drug Safety, 2011, 20, 1303-1310.	0.9	16
302	Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus–HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users. Addiction, 2012, 107, 152-159.	1.7	16
303	The effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to antiretroviral therapy: a Canadian-European collaborative retrospective cohort study. CMAJ Open, 2014, 2, E318-E329.	1.1	16
304	Prevention and Care of Hepatitis B in Senegal; Awareness and Attitudes of Medical Practitioners. American Journal of Tropical Medicine and Hygiene, 2017, 97, 389-395.	0.6	16
305	Atherogen lipid profile in HIV-1-infected patients with lipodystrophy syndrome. European Journal of Internal Medicine, 2000, 11, 257-263.	1.0	15
306	Effect of early chemoprophylaxis with co-trimoxazole on nutritional status evolution in HIV-1-infected adults in Abidjan, Côte d'Ivoire. Aids, 2001, 15, 869-876.	1.0	15

#	Article	IF	CITATIONS
307	Primary HIV-1 infection in African children infected through breastfeeding. Aids, 2002, 16, 2303-2309.	1.0	15
308	Obtaining informed consent from HIV-infected pregnant women, Abidjan, Côte d'Ivoire. Aids, 2004, 18, 1486-1488.	1.0	15
309	A multistate approach for estimating the incidence of human immunodeficiency virus by using data from a prevalent cohort study. Journal of the Royal Statistical Society Series C: Applied Statistics, 2005, 54, 739-752.	0.5	15
310	Prophylactic antiretroviral regimens for prevention of mother-to-child transmission of HIV in resource-limited settings. Current Opinion in HIV and AIDS, 2008, 3, 161-165.	1.5	15
311	High Levels of Alcohol Consumption Increase the Risk of Advanced Hepatic Fibrosis in HIV/Hepatitis C Virus-Coinfected Patients: A Sex-Based Analysis Using Transient Elastography at Enrollment in the HEPAVIH ANRS CO13 Cohort. Clinical Infectious Diseases, 2014, 59, 1190-1192.	2.9	15
312	Determinants of Weight Evolution Among HIV-Positive Patients Initiating Antiretroviral Treatment in Low-Resource Settings. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, 146-154.	0.9	15
313	Oral health and HIV infection among female sex workers in Abidjan, Côte d'Ivoire. BMC Oral Health, 2015, 15, 154.	0.8	15
314	A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virusâ€coinfected patients. Hepatology, 2016, 64, 1462-1472.	3.6	15
315	Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART. Journal of Antimicrobial Chemotherapy, 2019, 74, 473-479.	1.3	15
316	SHJGELLOSIS AT A CARIBBEAN RESORT. American Journal of Epidemiology, 1987, 126, 1173-1180.	1.6	14
317	CD4 Percentages and Total Lymphocyte Counts as Early Surrogate Markers for Pediatric HIV-1 Infection in Resource-Limited Settings. Journal of Tropical Pediatrics, 2006, 52, 346-354.	0.7	14
318	Tuberculosis in Pediatric Antiretroviral Therapy Programs in Low- and Middle-Income Countries: Diagnosis and Screening Practices. Journal of the Pediatric Infectious Diseases Society, 2015, 4, 30-38.	0.6	14
319	High prevalence of dental caries among HIVâ€infected children in <scp>W</scp> est <scp>A</scp> frica compared to uninfected siblings. Journal of Public Health Dentistry, 2017, 77, 234-243.	0.5	14
320	Implementing universal HIV treatment in a high HIV prevalence and rural South African setting – Field experiences and recommendations of health care providers. PLoS ONE, 2017, 12, e0186883.	1.1	14
321	Malaria, HIV and pregnancy. Aids, 2003, 17, 275-276.	1.0	14
322	Maternal and nenonatal tenofovir and emtricitabine to prevent vertical transmission of HIV-1: tolerance and resistance. Aids, 2010, 24, 2481-2488.	1.0	14
323	Incidence of Severe Neutropenia in HIV-Infected People Starting Antiretroviral Therapy in West Africa. PLoS ONE, 2017, 12, e0170753.	1.1	14
324	Pregnancy, body weight and human immunodeficiency virus infection in African women: a prospective cohort study in Kigali (Rwanda), 1992- 1994. Pregnancy and HIV Study Group (EGE). International Journal of Epidemiology, 1998, 27, 1072-1077.	0.9	13

#	Article	IF	CITATIONS
325	Prevention of infectious complications of paediatric HIV infection in Africa. Aids, 2000, 14, 1091-1099.	1.0	13
326	Infant Feeding Practices Before Implementing Alternatives to Prolonged Breastfeeding to Reduce HIV Transmission Through Breastmilk in Abidjan, Côte d'Ivoire. Journal of Tropical Pediatrics, 2005, 51, 351-355.	0.7	13
327	Association Between ALT Level and the Rate of Cardio/Cerebrovascular Events in HIV-Positive Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 456-463.	0.9	13
328	Incidence of Pregnancy After Antiretroviral Therapy Initiation and Associated Factors in 8 West African Countries. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, e45-e54.	0.9	13
329	Implementation and Operational Research. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, e5-e9.	0.9	13
330	Immunologic response in treatmentâ€naÃ⁻ve HIVâ€2â€infected patients: the IeDEA West Africa cohort. Journal of the International AIDS Society, 2016, 19, 20044.	1.2	13
331	Evaluation of Three Sampling Methods to Monitor Outcomes of Antiretroviral Treatment Programmes in Low- and Middle-Income Countries. PLoS ONE, 2010, 5, e13899.	1.1	13
332	HIV Infection among Pregnant Women in Bobo-Dioulasso, Burkina Faso: Comparison of Voluntary and Blinded Seroprevalence Estimates. International Journal of STD and AIDS, 1999, 10, 738-740.	0.5	12
333	Prognostic Factors of Combined Viral Load and CD4+ Cell Count Responses Under Triple Antiretroviral Therapy, Aquitaine Cohort, 1996–1998. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 27, 161-167.	0.9	12
334	Hepatitis B vaccination in HIV-infected patients: a survey of physicians and patients participating in the Aquitaine cohort. Gastroenterologie Clinique Et Biologique, 2006, 30, 189-195.	0.9	12
335	Feasibility and acceptability of rapid HIV screening in a labour ward in Togo. Journal of the International AIDS Society, 2012, 15, 17380.	1.2	12
336	Network for strong, national, public health institutes in west Africa. Lancet, The, 2016, 387, 2196-2197.	6.3	12
337	Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 311-318.	0.9	12
338	Etiology of hepatocellular carcinoma in <scp>W</scp> est <scp>A</scp> frica, a case–control study. International Journal of Cancer, 2018, 143, 869-877.	2.3	12
339	Prevention of HIV Transmission Through Breast-feeding: Strengthening the Research Agenda. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 167-168.	0.9	11
340	Knowledge, Attitudes, and Beliefs of Health Care Workers Regarding Alternatives to Prolonged Breast-Feeding (ANRS 1201/1202, Ditrame Plus, Abidjan, CÃ te d'Ivoire). Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 102-105.	0.9	11
341	Determinants of Smoking Cessation Attempts Among HIV-Infected Patients: Results from a Hospital-Based Prospective Cohort. Current HIV Research, 2010, 8, 212-217.	0.2	11
342	Insurability of HIV-positive people treated with antiretroviral therapy in Europe. Aids, 2013, 27, 1641-1655.	1.0	11

#	Article	IF	CITATIONS
343	Selfâ€reported alcohol abuse in <scp>HIV</scp> – <scp>HCV</scp> coâ€infected patients: a better predictor of <scp>HIV</scp> virological rebound than physician's perceptions (<scp>HEPAVIH ARNS CO</scp> 13) Tj ETQq2	l 1.Ø.7843	31141 rgBT /O
344	Impact of HCV Treatment and Depressive Symptoms on Adherence to Haart among HIV–HCV-Coinfected Patients: Results from the Anrs-Co13-Hepavih Cohort. Antiviral Therapy, 2014, 19, 171-178.	0.6	11
345	Risk Factors for Cervical Intraepithelial Neoplasia in HIV-Infected Women on Antiretroviral Treatment in Côte d'Ivoire, West Africa. PLoS ONE, 2014, 9, e90625.	1.1	11
346	Severe Morbidity According to Sex in the Era of Combined Antiretroviral Therapy: The ANRS CO3 Aquitaine Cohort. PLoS ONE, 2014, 9, e102671.	1.1	11
347	Integrating Electronic Patient-Reported Outcome Measures into Routine HIV Care and the ANRS CO3 Aquitaine Cohort's Data Capture and Visualization System (QuAliV): Protocol for a Formative Research Study. JMIR Research Protocols, 2018, 7, e147.	0.5	11
348	Virological characterization of an infection with a dual-tropic, multidrug-resistant HIV-1 and further evolution on antiretroviral therapy. Aids, 2007, 21, 103-106.	1.0	10
349	18-month occurrence of severe events among early diagnosed HIV-infected children before antiretroviral therapy in Abidjan, Côte d'Ivoire: A cohort study. BMC Public Health, 2008, 8, 169.	1.2	10
350	Nevirapine for the Prevention of Mother-to-Child Transmission of HIV: A Nation-Wide Coverage Survey in CÑte d'Ivoire. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, S3-S8.	0.9	10
351	Public sector services for the prevention of mother-to-child transmission of HIV infection: a micro-costing survey in Namibia and Rwanda. Bulletin of the World Health Organization, 2013, 91, 407-415.	1.5	10
352	Triple therapy with boceprevir or telaprevir in a <scp>E</scp> uropean cohort of cirrhotic <scp>HIV</scp> / <scp>HCV</scp> genotype 1 oinfected patients. Liver International, 2015, 35, 2090-2099.	1.9	10
353	Improvements over time in short-term mortality following myocardial infarction in HIV-positive individuals. Aids, 2016, 30, 1583-1596.	1.0	10
354	Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. Lancet HIV,the, 2017, 4, e251-e259.	2.1	10
355	Updating vital status by tracking in the community among patients with epidemic Kaposi sarcoma who are lost to follow-up in sub-Saharan Africa. BMC Cancer, 2017, 17, 611.	1.1	10
356	Gender differences in the use of cardiovascular interventions in <scp>HIV</scp> â€positive persons; the D:A:D Study. Journal of the International AIDS Society, 2018, 21, e25083.	1.2	10
357	Optimal breastfeeding durations for HIVâ€exposed infants: the impact of maternal <scp>ART</scp> use, infant mortality and replacement feeding risk. Journal of the International AIDS Society, 2018, 21, e25107.	1.2	10
358	Tenâ€year attrition and antiretroviral therapy response among HIVâ€positive adults: a sexâ€based cohort analysis from eight West African countries. Journal of the International AIDS Society, 2021, 24, e25723.	1.2	10
359	Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients. World Journal of Hepatology, 2018, 10, 856-866.	0.8	10
360	Stabilization of HIV infection rates in urban Burkina Faso, 1995–1999. International Journal of STD and AIDS, 2001, 12, 460-462.	0.5	9

#	Article	IF	CITATIONS
361	Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France). BMC Health Services Research, 2012, 12, 59.	0.9	9
362	Chronic Viral Hepatitis Is Associated With Low Bone Mineral Density in HIV-Infected Patients, ANRS CO 3 Aquitaine Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 430-435.	0.9	9
363	Modified renal function in pregnancy: impact on emtricitabine pharmacokinetics. British Journal of Clinical Pharmacology, 2014, 78, 1378-1386.	1.1	9
364	Aging with HIV: what effect on mortality and loss to follow-up in the course of antiretroviral therapy? The IeDEA West Africa Cohort Collaboration. HIV/AIDS - Research and Palliative Care, 2018, Volume 10, 239-252.	0.4	9
365	Assessment of the scaleâ€up of cervical cancer screening in Abidjan stratified by <scp>HIV</scp> status. International Journal of Gynecology and Obstetrics, 2019, 147, 246-251.	1.0	9
366	PMTCT care cascade and factors associated with attrition in the first four years after Option B+ implementation in Mozambique. Tropical Medicine and International Health, 2020, 25, 222-235.	1.0	9
367	Prevalence and factors associated with severe depressive symptoms in older west African people living with HIV. BMC Psychiatry, 2020, 20, 442.	1.1	9
368	Change in T-Lymphocyte Count after Initiation of Highly Active Antiretroviral Therapy in HIV-Infected Patients with History of <i>Mycobacterium Avium</i> Complex Infection. Antiviral Therapy, 2006, 11, 343-350.	0.6	9
369	BCG vaccination in children born to HIV-positive mothers. Lancet, The, 1992, 340, 799-800.	6.3	8
370	Universal antiretroviral therapy among pregnant and postpartum HIV-infected women would improve maternal health and decrease postnatal HIV transmission. Aids, 2010, 24, 1239-1241.	1.0	8
371	We still need to beat HIV. Science, 2017, 357, 335-335.	6.0	8
372	Increased liver stiffness is associated with mortality in HIV/HCV coinfected subjects: The French nationwide ANRS CO13 HEPAVIH cohort study. PLoS ONE, 2019, 14, e0211286.	1.1	8
373	Risk behaviors in volunteer blood donors who seroconverted for HIV, Abidjan, Côte d'Ivoire 1997 to 2005. Transfusion, 2010, 50, 888-893.	0.8	7
374	Effect of Hepatitis C Treatment on Cd4 ⁺ T-C El L Counts And The Risk Of Death In HIV–HCV-Coinfected Patients: The Cohere Collaboration. Antiviral Therapy, 2012, 17, 1541-1550.	0.6	7
375	Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settings. BMC Infectious Diseases, 2012, 12, 147.	1.3	7
376	Predictors of CD4+ T-Cell Counts of HIV Type 1–Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. Journal of Infectious Diseases, 2013, 207, 759-767.	1.9	7
377	Individualizing the WHO HIV and infant feeding guidelines. Aids, 2014, 28, S287-S299.	1.0	7
378	Short article: Fatigue in the long term after HCV treatment in HIV–HCV-coinfected patients: functional limitations persist despite viral clearance in patients exposed to peg-interferon/ribavirin-containing regimens (ANRS CO13-HEPAVIH cohort). European Journal of Gastroenterology and Hepatology, 2016, 28, 1003-1007.	0.8	7

#	Article	IF	CITATIONS
379	Low incidence of acute rejection within 6 months of kidney transplantation in HIVâ€infected recipients treated with raltegravir: the Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS) 153 TREVE trial. HIV Medicine, 2019, 20, 202-213.	1.0	7
380	Temporal trends of population viral suppression in the context of Universal Test and Treat: the ANRS 12249 TasP trial in rural South Africa. Journal of the International AIDS Society, 2019, 22, e25402.	1.2	7
381	Tuberculosis and chemoprophylaxis in Africa. Lancet, The, 1995, 345, 867-868.	6.3	6
382	Immune Status and Uptake of Antiretroviral Interventions to Prevent Mother-to-Child Transmission of HIV-1 in Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 36, 755-757.	0.9	6
383	Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort. Journal of Clinical Virology, 2006, 36, 95-99.	1.6	6
384	Correlates of HIV sustained viral suppression in HIV/hepatitis C virus coinfected patients. Aids, 2014, 28, 1155-1160.	1.0	6
385	The Impact of the 2013 WHO Antiretroviral Therapy Guidelines on the Feasibility of HIV Population Prevention Trials. HIV Clinical Trials, 2014, 15, 185-198.	2.0	6
386	Boosted Lopinavir– Versus Boosted Atazanavir–Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries. Clinical Infectious Diseases, 2015, 60, 1262-1268.	2.9	6
387	Assessing the psychometric properties of the French WHOQOL-HIV BREF within the ANRS CO3 Aquitaine Cohort's QuAliV ancillary study. Health and Quality of Life Outcomes, 2020, 18, 220.	1.0	6
388	Atherosclerotic Cardiovascular Events in Patients Infected With Human Immunodeficiency Virus and Hepatitis C Virus. Clinical Infectious Diseases, 2021, 72, e215-e223.	2.9	6
389	Early ART Initiation Improves HIV Status Disclosure and Social Support in People Living with HIV, Linked to Care Within a Universal Test and Treat Program in Rural South Africa (ANRS 12249 TasP Trial). AIDS and Behavior, 2021, 25, 1306-1322.	1.4	6
390	Cerebral alterations in West African HIV and non-HIV adults aged ≥50: An MRI study. International Journal of Infectious Diseases, 2021, 103, 457-463.	1.5	6
391	Prevalence and factors associated with physical function limitation in older West African people living with HIV. PLoS ONE, 2020, 15, e0240906.	1.1	6
392	Should nevirapine be used to prevent mother-to-child transmission of HIV among women of unknown serostatus?. Bulletin of the World Health Organization, 2005, 83, 224-8.	1.5	6
393	Zidovudine and Breast-Feeding. AIDS Patient Care and STDs, 1997, 11, 4-5.	1.1	5
394	Vitamin A supplementation and HIV-1 mother-to-child transmission in Africa. Lancet, The, 1998, 352, 653-654.	6.3	5
395	Using patient-reported outcomes to improve the management of co-infection with HIV and HCV: the ANRS CO13 HEPAVIH cohort. Expert Review of Gastroenterology and Hepatology, 2014, 8, 351-358.	1.4	5
396	HIV Ascertainment through Repeat Home-based Testing in the Context of a Treatment as Prevention Trial (ANRS 12249 TasP) in Rural South Africa. AIDS Research and Human Retroviruses, 2014, 30, A287-A287.	0.5	5

#	Article	IF	CITATIONS
397	Test and treat all as soon as possible. The Lancet Global Health, 2014, 2, e2-e3.	2.9	5
398	Smoking status and HIV in low-income and middle-income countries. The Lancet Global Health, 2017, 5, e557-e558.	2.9	5
399	Couples HIV counselling and couple relationships in India, Georgia and the Dominican Republic. BMC Public Health, 2017, 17, 901.	1.2	5
400	"lf you are here at the clinic, you do not know how many people need help in the community― Perspectives of home-based HIV services from health care workers in rural KwaZulu-Natal, South Africa in the era of universal test-and-treat. PLoS ONE, 2018, 13, e0202473.	1.1	5
401	Eliminating HIV transmission through breast milk from women taking antiretroviral drugs. BMJ, The, 2021, 374, n1697.	3.0	5
402	Incidence of pregnancies among African HIV-infected women, Abidjan, 1995–2000. Aids, 2001, 15, 2327-2330.	1.0	5
403	HIV-1 Evolutionary Dynamics under Nonsuppressive Antiretroviral Therapy. MBio, 2022, 13, e0026922.	1.8	5
404	Surveillance of heterosexually acquired HIV infection and AIDS. Lancet, The, 1995, 346, 308-309.	6.3	4
405	Children and HIV in Africa: what is next?. Lancet, The, 2003, 362, 1597-1598.	6.3	4
406	Alternative methods to analyse the impact of HIV mutations on virological response to antiviral therapy. BMC Medical Research Methodology, 2008, 8, 68.	1.4	4
407	Tolerance and viral resistance after single-dose nevirapine (NVP) and short-course of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) to prevent mother-to-child transmission (PMTCT) of HIV-1: the TEmAA ANRS 12109 phase II trial, step 1. Retrovirology, 2008, 5, O20.	0.9	4
408	Information That Should Be Given to HIV Cohort Participants during Ongoing Research: The Viewpoints of Patient Representatives and Research Professionals. Journal of Empirical Research on Human Research Ethics, 2011, 6, 76-83.	0.6	4
409	HIV-1 Tropism and Liver Fibrosis in HIV–HCV Co-Infected Patients. PLoS ONE, 2012, 7, e50289.	1.1	4
410	Factors Associated with HIV Testing History among Pregnant Women and Their Partners in Georgia: The ANRS 12127 Prenahtest Trial. AIDS Research and Treatment, 2014, 2014, 1-6.	0.3	4
411	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. Journal of Antimicrobial Chemotherapy, 2016, 71, 1352-1360.	1.3	4
412	Serum suppression of tumorigenicity 2 level is an independent predictor of all-cause mortality in HIV-infected patients. Aids, 2017, 31, 2355-2365.	1.0	4
413	Barriers influencing task-shifting for the management of depression in people living with HIV: a study from West Africa leDEA cohort collaboration. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2021, 33, 352-356.	0.6	4
414	Short article: Anger and quality of life in patients co-infected with HIV and hepatitis C virus: a cross-sectional study (ANRS CO13-HEPAVIH). European Journal of Gastroenterology and Hepatology, 2017, 29, 786-791.	0.8	4

#	Article	IF	CITATIONS
415	Change in T-lymphocyte count after initiation of highly active antiretroviral therapy in HIV-infected patients with history of Mycobacterium avium complex infection. Antiviral Therapy, 2006, 11, 343-50.	0.6	4
416	Cancer incidence in a cohort of human immunodeficiency virus seroconverters. , 1998, 82, 996-998.		3
417	Late postnatal mother-to-child transmission of HIV-1. Lancet, The, 1998, 352, 1630.	6.3	3
418	Behavior Assessment of Blood Donors Facing the Risk of HIV Infection, Abidjan, Côte D'Ivoire, 2001-2002. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 38, 618-621.	0.9	3
419	Evidence behind the WHO Guidelines: Hospital Care for Children: What Antiretroviral Agents and Regimens are Effective in the Prevention of Mother-to-child Transmission of HIV?. Journal of Tropical Pediatrics, 2005, 52, 235-238.	0.7	3
420	Mortality of infants born to HIV-infected mothers in Africa. Lancet, The, 2005, 365, 121-122.	6.3	3
421	Immunological response to highly active antiretroviral therapy following treatment for prevention of mother to child transmission of HIVâ€l: a study in Côte d'Ivoire. Journal of the International AIDS Society, 2010, 13, 28-28.	1.2	3
422	Health Care Resource Utilization in Untreated HIV-Infected Children in A Pediatric Programme, Abidjan, CÑte d'Ivoire, 2004–2009. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, e14-e21.	0.9	3
423	Dried cervical spots for human papillomaviruses identification. Journal of Medical Virology, 2013, 85, 1222-1228.	2.5	3
424	Handgrip Strength Is Only Weakly Correlated With Physical Function in Well-Controlled HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, e25-e27.	0.9	3
425	Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes. Medicine (United States), 2016, 95, e5133.	0.4	3
426	No effect of test and treat on sexual behaviours at population level in rural South Africa. Aids, 2019, 33, 709-722.	1.0	3
427	Chronic viral hepatitis, <scp>HIV</scp> infection and <scp>Nonâ€Hodgkin</scp> lymphomas in West Africa, a caseâ€control study. International Journal of Cancer, 2021, 149, 1536-1543.	2.3	3
428	In utero exposure to antiretroviral drugs and pregnancy outcomes: Analysis of the French ANRS pharmacovigilance database. British Journal of Clinical Pharmacology, 2022, 88, 942-964.	1.1	3
429	Medical care costs of children born to HIV-infected mothers, in Abidjan, Côte d'Ivoire 1996–1997. Aids, 2000, 14, 1076.	1.0	3
430	Thresholds of CD4 cells for initiating trimethoprim-sulfamethoxazole prophylaxis in west Africa. Aids, 2000, 14, 2628-2629.	1.0	3
431	Fitting a vaccine into the HIV prevention landscape. Journal of the International AIDS Society, 2021, 24, e25792.	1.2	3
432	Safety of Haemophilus influenzae conjugate vaccine in children born to HIV-1 infected mothers: Kigali (Rwanda), 1992–1994. Vaccine, 1996, 14, 177-178.	1.7	2

#	Article	IF	CITATIONS
433	CD4 count and CD4% in African HIV-infected people. International Journal of Epidemiology, 1998, 27, 928-928.	0.9	2
434	Dietary Problems in African HIV-1–Infected Adults, Abidjan, Côte d'Ivoire. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 23, 357-358.	0.9	2
435	Mortality of HIV-infected patients in low-income countries – Authors' response. Lancet, The, 2006, 368, 2207-2208.	6.3	2
436	Implementation and Operational Research in Francophone Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, S1-S2.	0.9	2
437	When should therapy begin for children infected with HIV?. Lancet Infectious Diseases, The, 2012, 12, 900-902.	4.6	2
438	Hepatitis C virus RNA quantitation in a nationwide French cohort of patients co-infected with HIV and HCV: Should the same test be applied to all samples?. Journal of Virological Methods, 2012, 181, 131-133.	1.0	2
439	Prevalence of Mycoplasma genitalium Among HIV-Infected Women, Agence Nationale de Recherches sur le SIDA et les hépatites virales CO3 Aquitaine Cohort, France. Sexually Transmitted Diseases, 2013, 40, 653-654.	0.8	2
440	Antiretroviral treatment response of HIVâ€infected children after prevention of motherâ€toâ€child transmission in West Africa. Journal of the International AIDS Society, 2014, 17, 18737.	1.2	2
441	Severe morbidity after antiretroviral (ART) initiation: active surveillance in HIV care programs, the IeDEA West Africa collaboration. BMC Infectious Diseases, 2015, 15, 176.	1.3	2
442	Absence of Decline of Kidney Function in Human Immunodeficiency Virus-Infected Patients Under Routine Clinical Management. Nephron, 2017, 136, 211-220.	0.9	2
443	Prevalence of hepatitis C among HIV-1, HIV-2 and dually reactive patients: A multi-country cross-sectional survey in West Africa. Journal of Public Health in Africa, 2018, 9, 871.	0.2	2
444	Human papilloma viruses infection among adolescent females perinatally infected with HIV in Côte d'Ivoire. Sexually Transmitted Infections, 2021, 97, 238-243.	0.8	2
445	Web-Based Module for the Collection of Electronic Patient-Reported Outcomes in People Living With HIV in Nouvelle Aquitaine, France: Usability Evaluation. JMIR Formative Research, 2019, 3, e15013.	0.7	2
446	Early HIV treatment and survival over six years of observation in the ANRS 12249 Treatment as Prevention Trial. HIV Medicine, 2022, , .	1.0	2
447	MEASLES CONTROL IN AFRICA. Lancet, The, 1986, 328, 162-163.	6.3	1
448	Improper practices for diarrhoea treatment in Africa. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1988, 82, 935-936.	0.7	1
449	Telematics and sentinel health information system with general practitioners in Aquitaine, southwest France. Medical Informatics = Medecine Et Informatique, 1989, 14, 281-286.	0.8	1
450	Increase in CD3+ CD4- T lymphocytes in patients with AIDS and disseminated Mycobacterium avium-intracellulare complex infection: a prospective study. Microbes and Infection, 1999, 1, 771-776.	1.0	1

#	Article	IF	CITATIONS
451	Hepatitis B and HIV type 1 co-infection in pregnant African women. Médecine Et Maladies Infectieuses, 2002, 32, 396-397.	5.1	1
452	Development of resistance after administration of single-dose nevirapine to prevent mother-to-child transmission of HIV. Future HIV Therapy, 2007, 1, 91-101.	0.5	1
453	Editorial Commentary: Turning the Tide on HIV in Women and Children: Preventing Breast-Milk HIV Transmission While Increasing Maternal Life Expectancy. Clinical Infectious Diseases, 2013, 56, 140-142.	2.9	1
454	Preface. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, S1-S2.	0.9	1
455	Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote d'lvoire West Africa. PLoS ONE, 2020, 15, e0236642.	1.1	1
456	Incidence of Tuberculosis During the First Year of Antiretroviral Treatment in West African HIV-Infected Adults. Open Forum Infectious Diseases, 2020, 7, ofaa203.	0.4	1
457	Maternal vitamin A status and mother-to-child transmission of HIV in West Africa. Aids, 2000, 14, 908.	1.0	1
458	Sexual and Reproductive Life of Women Informed of Their HIV Seropositivity: A Prospective Cohort Study in Burkina Faso. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 28, 367-372.	0.9	1
459	Assessment of dietary diversity and nutritional support for children living with HIV in the IeDEA pediatric West African cohort: a non-comparative, feasibility study. BMC Nutrition, 2021, 7, 83.	0.6	1
460	Costs and economies of scale in repeated home-based HIV counselling and testing: Evidence from the ANRS 12249 Treatment as Prevention trial in South Africa. Social Science and Medicine, 2022, 305, 115068.	1.8	1
461	The effect of cotrimoxazole coadministrated with antituberculous drugs on serum transaminases in HIV-infected adults from the Ivory Coast. British Journal of Clinical Pharmacology, 2001, 52, 611-612.	1.1	0
462	Short-course antiretroviral treatment may reduce mother-to-child HIV-1 transmission during delivery. Evidence-Based Healthcare and Public Health, 2002, 6, 165-166.	0.0	0
463	CMV plasma DNAemia and risk of cancer among HIV-infected patients: A case–control study nested in the ANRS CO3 Aquitaine Cohort, France, 2002–2007. Journal of Clinical Virology, 2011, 50, 177-180.	1.6	0
464	Discussion on the effect of age on immunological response in the first year of antiretroviral therapy in HIV-1-infected adults. Aids, 2013, 27, 146-147.	1.0	0
465	Title is missing!. , 2020, 15, e0240906.		0
466	Title is missing!. , 2020, 15, e0240906.		0
467	Title is missing!. , 2020, 15, e0240906.		0
468	Title is missing!. , 2020, 15, e0240906.		0

#	Article	IF	CITATIONS
469	Title is missing!. , 2020, 15, e0240906.		0
470	Title is missing!. , 2020, 15, e0240906.		0